Detalhe da pesquisa
1.
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
N Engl J Med
; 388(8): 706-718, 2023 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36812434
2.
Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients.
Haemophilia
; 30(3): 671-677, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575549
3.
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study).
Haemophilia
; 30(1): 98-105, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37983883
4.
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.
Haematologica
; 108(5): 1322-1334, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36655430
5.
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A.
Haemophilia
; 29(4): 1032-1038, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37252898
6.
No difference in quality of life between persons with severe haemophilia A and B.
Haemophilia
; 29(4): 987-996, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36791275
7.
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
Haemophilia
; 29(4): 1087-1094, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37347645
8.
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A - A modified Delphi consensus by the ADVANCE Working Group.
Haemophilia
; 29(1): 21-32, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36271497
9.
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81-8973.
Haemophilia
; 28(2): 223-229, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35005818
10.
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
Haemophilia
; 28(5): 713-719, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35575446
11.
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires.
Haemophilia
; 28(1): 18-26, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34761474
12.
Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?
Haemophilia
; 28(2): 215-222, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34918839
13.
Pain, depression and anxiety in people with haemophilia from three Nordic countries: Cross-sectional survey data from the MIND study.
Haemophilia
; 28(4): 557-567, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35460313
14.
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) - Unmet needs remain.
Haemophilia
; 28(3): 453-461, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35263495
15.
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.
Blood
; 134(22): 1973-1982, 2019 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31444162
16.
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa.
Haemophilia
; 27(3): 417-424, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33751755
17.
Recombinant FVIIa in elective non-orthopaedic surgery of adults with haemophilia and inhibitors: A systematic literature review.
Haemophilia
; 27(3): e314-e330, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33751769
18.
Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays.
Haemophilia
; 27(3): 494-500, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33866649
19.
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A.
Haemophilia
; 27(4): 626-633, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33966319
20.
The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B.
Haemophilia
; 27(5): 802-813, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34118102